Induced pluripotent stem cells as a new getaway for bone tissue engineering: A systematic review

Bastami, Farshid; Nazeman, Pantea; Moslemi, Hamidreza; Rad, Maryam Rezai; Sharifi, Kazem; Khojasteh, Arash

doi:10.1111/cpr.12321

“…There have been a number of reports on the differentiation of human ESCs (hESCs) and iPSCs into osteogenic cells through the formation of embryoid bodies, spontaneous differentiation, indirect co-culture with osteogenic cells, treatment with conditioned medium generated by osteogenic cells, or use of various schemes for direct osteogenic differentiation. 5 However, for the most part, the results have relied on in vitro differentiation assays that may not reflect capabilities in vivo, and results from limited studies involving in vivo transplantation are not conclusive. [6][7][8][9] Furthermore, most studies use ectopic transplantation sites rather than sites within an injured skeletal tissue that would better mimic a clinical scenario.…”

Section: Pluripotent Stem Cells (Embryonic Stem Cells) and Induced Plmentioning

confidence: 99%

“…• Studies should consider cell autonomous and non-cell autonomous mechanisms of influence of cell-based therapies. 5. What are the Task Force recommendations for preclinical and clinical studies of cell-based therapies?…”

mentioning

confidence: 99%

American Society for Bone and Mineral Research‐Orthopaedic Research Society Joint Task Force Report on Cell‐Based Therapies – Secondary Publication

O’Keefe

¹

,

Tuan

²

,

Lane

³

et al. 2020

Journal Orthopaedic Research

View full text Add to dashboard Cite

Cell‐based therapies, defined here as the delivery of cells in vivo to treat disease, have recently gained increasing public attention as a potentially promising approach to restore structure and function to musculoskeletal tissues. Although cell‐based therapy has the potential to improve the treatment of disorders of the musculoskeletal system, there is also the possibility of misuse and misrepresentation of the efficacy of such treatments. The medical literature contains anecdotal reports and research studies, along with web‐based marketing and patient testimonials supporting cell‐based therapy. Both the American Society for Bone and Mineral Research (ASBMR) and the Orthopaedic Research Society (ORS) are committed to ensuring that the potential of cell‐based therapies is realized through rigorous, reproducible, and clinically meaningful scientific discovery. The two organizations convened a multidisciplinary and international Task Force composed of physicians, surgeons, and scientists who are recognized experts in the development and use of cell‐based therapies. The Task Force was charged with defining the state‐of‐the art in cell‐based therapies and identifying the gaps in knowledge and methodologies that should guide the research agenda. The efforts of this Task Force are designed to provide researchers and clinicians with a better understanding of the current state of the science and research needed to advance the study and use of cell‐based therapies for skeletal tissues. The design and implementation of rigorous, thorough protocols will be critical to leveraging these innovative treatments and optimizing clinical and functional patient outcomes. In addition to providing specific recommendations and ethical considerations for preclinical and clinical investigations, this report concludes with an outline to address knowledge gaps in how to determine the cell autonomous and nonautonomous effects of a donor population used for bone regeneration. © 2020 Orthopaedic Research Society. Published by Wiley Periodicals, Inc. J Orthop Res 38:485–502, 2020

show abstract

“…(5) However, for the most part, the results have relied on in vitro differentiation assays that may not reflect capabilities in vivo, and results from limited studies involving in vivo transplantation are not conclusive. Pluripotency refers to the potential of a stem cell to differentiate into cells of all three germ layers-endoderm, mesoderm, and ectoderm.…”

Section: Pluripotent Stem Cells (Embryonic Stem Cells) and Induced Plmentioning

confidence: 99%

American Society for Bone and Mineral Research-Orthopaedic Research Society Joint Task Force Report on Cell-Based Therapies

O’Keefe

¹

,

Tuan

²

,

Lane

³

et al. 2019

Journal of Bone and Mineral Research

View full text Add to dashboard Cite

Cell‐based therapies, defined here as the delivery of cells in vivo to treat disease, have recently gained increasing public attention as a potentially promising approach to restore structure and function to musculoskeletal tissues. Although cell‐based therapy has the potential to improve the treatment of disorders of the musculoskeletal system, there is also the possibility of misuse and misrepresentation of the efficacy of such treatments. The medical literature contains anecdotal reports and research studies, along with web‐based marketing and patient testimonials supporting cell‐based therapy. Both the American Society for Bone and Mineral Research (ASBMR) and the Orthopaedic Research Society (ORS) are committed to ensuring that the potential of cell‐based therapies is realized through rigorous, reproducible, and clinically meaningful scientific discovery. The two organizations convened a multidisciplinary and international Task Force composed of physicians, surgeons, and scientists who are recognized experts in the development and use of cell‐based therapies. The Task Force was charged with defining the state‐of‐the art in cell‐based therapies and identifying the gaps in knowledge and methodologies that should guide the research agenda. The efforts of this Task Force are designed to provide researchers and clinicians with a better understanding of the current state of the science and research needed to advance the study and use of cell‐based therapies for skeletal tissues. The design and implementation of rigorous, thorough protocols will be critical to leveraging these innovative treatments and optimizing clinical and functional patient outcomes. In addition to providing specific recommendations and ethical considerations for preclinical and clinical investigations, this report concludes with an outline to address knowledge gaps in how to determine the cell autonomous and nonautonomous effects of a donor population used for bone regeneration. © 2019 American Society for Bone and Mineral Research.

show abstract

“…However, the proliferation rates and osteogenic differentiation abilities of BMSCs decrease during cell culture expansion in vitro and with age (H. T. Chen et al, 2012). Induced pluripotent stem cells (iPSCs) have better-unlimited growth capability and pluripotency than BMSCs (Bastami et al, 2017). Furthermore, the extraction of iPSCs from the patients' own somatic cells constitutes one of the major breakthroughs in tissue regeneration (Huangfu et al, 2008).…”

mentioning

confidence: 99%

Rapid human‐derived iPSC osteogenesis combined with three‐dimensionally printed Ti6Al4V scaffolds for the repair of bone defects

Yu

¹

,

Yong

²

,

Zhang

³

et al. 2020

Journal Cellular Physiology

View full text Add to dashboard Cite

Human‐induced pluripotent stem cells (iPSCs) are an alternative source of mesenchymal stem cells used for bone regeneration. However, the current osteogenically induced methods for iPSCs are slow and complex. We have used retinoic acid (RA) to induce osteogenic iPSCs within 10 days and assess whether a rapid differentiation could improve the osteogenic potential of the three‐dimensionally printed Ti6Al4V (3DTi) scaffolds. First, the osteogenic differentiation of iPSCs was induced with RA, and the osteogenic potential of iPSCs was evaluated using standard assays. In addition, a 5‐mm mandibular bone defect was generated in rats and was repaired with 3DTi scaffolds that were seeded with iPSC‐induced osteoblasts. The capacity of seeded scaffolds for the enhancement of bone regeneration in vivo was assessed. Finally, we tested the potential mechanisms of RA‐dependent iPSC bone induction and its effect on the Wnt/β‐catenin pathway. The results showed that iPSCs could form osteocytes within 10 days. Animal experiments confirmed that rapid osteo‐induced iPSCs could enhance the bone regeneration and osteointegration capacity of the 3DTi scaffolds. Mechanistically, RA could activate the AKT/GSK3β/β‐catenin pathway during the process of iPSCs osteogenesis. The rapid osteoinduction of iPSCs combined with 3DTi scaffolds is a safe, effective, and reproducible method for repairing mandibular bone defects.

show abstract

Induced pluripotent stem cells as a new getaway for bone tissue engineering: A systematic review

Cited by 45 publications

References 103 publications

American Society for Bone and Mineral Research‐Orthopaedic Research Society Joint Task Force Report on Cell‐Based Therapies – Secondary Publication

American Society for Bone and Mineral Research‐Orthopaedic Research Society Joint Task Force Report on Cell‐Based Therapies – Secondary Publication

American Society for Bone and Mineral Research-Orthopaedic Research Society Joint Task Force Report on Cell-Based Therapies

Rapid human‐derived iPSC osteogenesis combined with three‐dimensionally printed Ti6Al4V scaffolds for the repair of bone defects

Contact Info

Product

Resources

About